"Feeling better" or "feeling well" in usual care of hip and knee osteoarthritis pain: Determination of cutoff points for patient acceptable symptom state (PASS) and minimal clinically important improvement (MCII) at rest and on movement in a national multicenter cohort study of 2414 patients with painful osteoarthritis

被引:43
作者
Perrot, Serge [1 ]
Bertin, Philippe [2 ]
机构
[1] Univ Paris 05, Serv Med Interne & Therapeut, Hotel Dieu, AP HP,INSERM U987, F-7500 Paris, France
[2] CHU Dupuytren, Serv Rhumatol, Limoges, France
关键词
Acceptability; Clinically relevance; Osteoarthritis; Pain; IMPORTANT-DIFFERENCE; REPORTED OUTCOMES; HEALTH-STATUS; QUESTIONNAIRE; CRITERIA; TRIALS; TIME;
D O I
10.1016/j.pain.2012.10.017
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Patient-reported outcome measures are being developed for more relevant assessments of pain management. The patient acceptable symptom state (PASS) ("feeling well") and the minimal clinically important improvement (MCII) ("feeling better") have been determined in clinical trials, but not in daily pain management. We carried out a national multicenter cohort study of patients over the age of 50 years with painful knee osteoarthritis (KOA) or hip osteoarthritis (HOA) who had visited their general practitioner and required treatment for more than 7 days. Overall, 2414 patients (50.2% men, mean age 67.3 years, body mass index 27.9 kg/m(2), 33.5% with HOA) were enrolled by 1116 general practitioners. After 7 days of treatment, PASS was estimated on a numerical rating scale as 4 at rest and 5 on movement, for both HOA and KOA, above the PASS threshold in clinical trials. In KOA, PASS was more frequently reached in men and younger people with less pain at rest and on movement, and in patients specifically seeking an improvement during sport activities. In HOA, PASS was most frequently reached in patients with low levels of pain at risk and in nonobese patients. MCII was -1 numerical rating scale point after 7 days of usual treatment. This improvement is smaller than that recorded in randomized controlled trials, and was the same for both sites, both at rest and on movement. In conclusion, patient-reported outcome values in daily practice differ from those in clinical trials, and their determinant factors may depend on the site of osteoarthritis. Assessments of the treatment of painful osteoarthritis should be adapted to the characteristics and daily life of the patient, to personalize patient management. (C) 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:248 / 256
页数:9
相关论文
共 25 条
[1]   DEVELOPMENT OF CRITERIA FOR THE CLASSIFICATION AND REPORTING OF OSTEOARTHRITIS - CLASSIFICATION OF OSTEOARTHRITIS OF THE KNEE [J].
ALTMAN, R ;
ASCH, E ;
BLOCH, D ;
BOLE, G ;
BORENSTEIN, D ;
BRANDT, K ;
CHRISTY, W ;
COOKE, TD ;
GREENWALD, R ;
HOCHBERG, M ;
HOWELL, D ;
KAPLAN, D ;
KOOPMAN, W ;
LONGLEY, S ;
MANKIN, H ;
MCSHANE, DJ ;
MEDSGER, T ;
MEENAN, R ;
MIKKELSEN, W ;
MOSKOWITZ, R ;
MURPHY, W ;
ROTHSCHILD, B ;
SEGAL, M ;
SOKOLOFF, L ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1986, 29 (08) :1039-1049
[2]   What is a good patient reported outcome after total hip replacement? [J].
Arden, N. K. ;
Kiran, A. ;
Judge, A. ;
Biant, L. C. ;
Javaid, M. K. ;
Murray, D. W. ;
Carr, A. J. ;
Cooper, C. ;
Field, R. E. .
OSTEOARTHRITIS AND CARTILAGE, 2011, 19 (02) :155-162
[3]   Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research [J].
Beaton, DE ;
Boers, M ;
Wells, GA .
CURRENT OPINION IN RHEUMATOLOGY, 2002, 14 (02) :109-114
[4]  
Creamer P, 1999, J RHEUMATOL, V26, P1785
[5]   Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis [J].
Dougados, Maxime ;
Moore, Alan ;
Yu, Shaohua ;
Gitton, Xavier .
ARTHRITIS RESEARCH & THERAPY, 2007, 9 (01)
[6]  
Ehrich EW, 2000, J RHEUMATOL, V27, P2635
[7]   Patient acceptable symptom state and OMERACT-OARSI set of responder criteria in joint replacement. Identification of cut-off values [J].
Escobar, A. ;
Gonzalez, M. ;
Quintana, J. M. ;
Vrotsou, K. ;
Bilbao, A. ;
Herrera-Espineira, C. ;
Garcia-Perez, L. ;
Aizpuru, F. ;
Sarasqueta, C. .
OSTEOARTHRITIS AND CARTILAGE, 2012, 20 (02) :87-92
[8]   Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis [J].
Heiberg, T. ;
Kvien, T. K. ;
Mowinckel, P. ;
Aletaha, D. ;
Smolen, J. S. ;
Hagen, K. B. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) :967-971
[9]   Clinically Relevant Outcomes Based on Analysis of Pooled Data from 2 Trials of Duloxetine in Patients with Knee Osteoarthritis [J].
Hochberg, Marc C. ;
Wohlreich, Madelaine ;
Gaynor, Paula ;
Hanna, Sylvia ;
Risser, Rick .
JOURNAL OF RHEUMATOLOGY, 2012, 39 (02) :352-358
[10]  
Hutchings A, 2007, J RHEUMATOL, V34, P2291